Navigation Links
Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors

y of XL999. Secondary objectives were to assess progression-free survival, duration of response, and overall survival with XL999. Patients in the studies received a once-weekly, 4-hour intravenous infusion of XL999 dosed at 2.4 mg/kg.

"We believe this integrated report provides a clear basis for the further development of XL999 with an appropriate risk-benefit profile," said Gisela M. Schwab, MD, senior vice president and chief medical officer at Exelixis. "On the basis of these data, further clinical evaluation of XL999 is planned in patients with stage IIIB-IV NSCLC in a Phase I dose-escalation study."

Integrated results from 79 patients who participated in the Phase II trials show preliminary evidence of XL999 activity in patients with NSCLC or AML. Of nine patients in the trial with NSCLC, two had partial responses (6 months and 11+ months), and three had stable disease for at least three months. Fourteen AML patients participated in the trial, of which ten had circulating myeloblasts. Eight of these ten patients experienced at least a 50% reduction in circulating myeloblasts following administration of XL999, one of whom achieved a partial response. Three of the 14 AML patients were found to have activating mutations in FLT3, including the patient who achieved a partial response. All three of these patients experienced a greater than 98% reduction in circulating myeloblasts.

With respect to the safety of XL999, serious cardiac adverse events occurred in 11 of the 79 patients (14%). These events were associated with the dose rate of XL999 and generally were associated with the first dose. Cardiac adverse events varied in severity, ranging from asymptomatic ECG changes to cardiopulmonary failure, and usually improved with discontinuation of XL999. Nine other non-cardiac serious adverse events associated with XL999 were reported: diarrhea (1), asthenia (1), pyrexia (2), hypersensitivity (2), vena cava thrombosis (1), dehydration (1), and pulmo
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:12/16/2009)... -- Today, Avantium announced the,appointment of Gunnar ... pharmaceutical,business. Gunnar Staaf previously worked at Serentis ... Company, in a range of commercial and ... in Avantium,s plan to,spin-out its pharmaceutical business. ... company based on its offering of proprietary,crystallization ...
(Date:12/16/2009)... Dec. 16 GlaxoSmithKline plc [GSK] (NYSE: ... announced an exclusive licensing agreement in the United ... of NB-001, a novel, patented compound representing the ... Developed by NanoBio, NB-001 provides significant antimicrobial activity ... herpes labialis . ,, Cold sores are ...
(Date:12/16/2009)... AARP Illinois Disappointed By Senate Vote Against Lower ... The U.S. Senate on Tuesday night ... Affordable Care Act that would help make prescription ... and legal importation of lower priced drugs from ... and sponsored by Senators Dorgan, Snowe, McCain, Grassley ...
Breaking Medicine Technology:Avantium Appoints Gunnar Staaf as CEO Pharma 2GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment 2AARP Illinois Key Vote News Alert 2Clinical Studies Validate Cancer Gene Delivery Platform 3A Landmark Publication Confirms Rexin G Effectively Targets Metastatic Cancers and Improves P 49657 1Clinical Studies Validate Cancer Gene Delivery Platform 3A Landmark Publication Confirms Rexin G Effectively Targets Metastatic Cancers and Improves P 49657 2Environmental Tectonics Corporations BioMedical Division Achieves Foreign Manufacturer Accreditation in Japan 12731 1Environmental Tectonics Corporations BioMedical Division Achieves Foreign Manufacturer Accreditation in Japan 12731 2Environmental Tectonics Corporations BioMedical Division Achieves Foreign Manufacturer Accreditation in Japan 12731 3Environmental Tectonics Corporations BioMedical Division Achieves Foreign Manufacturer Accreditation in Japan 12731 4PhRMA Statement on AARP White House Press Conference 12729 1PhRMA Statement on AARP White House Press Conference 12729 2
(Date:12/17/2009)... from MediNiche provide alternative natural relief prior to considering drugs. ... ... December 17, 2009 -- D-Psoria products are the ... associated with severe skin conditions . Developed by ... by MediNiche Pharmaceuticals, St. Louis, Missouri., , ,D-Psoria ...
(Date:12/17/2009)... complex personal injury and insurance cases, recognized for exceptional appellate work ... ... Nexis) December 17, 2009 -- Jody Nathan , a respected ... injury and insurance coverage disputes, has been named by Oklahoma Super ... of Oklahoma for 2009-2010., , ,Only five percent of the lawyers ...
(Date:12/16/2009)... Dec. 17 Health care sector revenue ... trillion, up from $1.66 trillion in 2007, according ... This sector is classified under the North American ... http://www.newscom.com/cgi-bin/prnh/20090226/CENSUSLOGO ) ,, These figures come from ... and Social Assistance , a series of tables ...
(Date:12/16/2009)... Dec. 16 New Enterprise Associates, Inc. ... announced that one of its portfolio companies, Acclarent, ... be acquired by Ethicon, Inc., a Johnson & ... $785 million (net of estimated cash on hand ... dedicated to designing, developing and commercializing devices that ...
(Date:12/16/2009)... WASHINGTON, Dec. 16 Losing has never felt ... knows maintaining his healthy new lifestyle means continuing to ... Drinking fat free milk is one healthy choice that ... a simple step everyone can take. Every glass of ... muscle, potassium to help maintain normal blood pressure, and ...
Breaking Medicine News(10 mins):Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 2Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 3Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 4Health News:Jody Nathan, Highly Regarded Tulsa Attorney, Named to 2009 Oklahoma Super Lawyers List 2Health News:Census Bureau: Health Care Industries Showed Modest Growth in Revenue in 2008 2Health News:Census Bureau: Health Care Industries Showed Modest Growth in Revenue in 2008 3Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3
... developed at the University at Buffalo has killed every ... airborne spores, viruses and bacteria in independent tests conducted ... prototype produced by Buffalo BioBlower Technologies LLC, a UB ... better than one part per million in an independent ...
... Dental Experts to Advance ... of CCLAD in Dentistry, LIVINGSTON, N.J., Feb. 28 ... leader in,advanced injection technologies, today reported that earlier this ... (CCLAD) Summit in New Orleans. The Summit welcomed a ...
... Out of Poverty on Average Pays,for Itself and ... LOS ANGELES, Feb. 28 Close to ... today at the Milken,Institute for the West Coast ... the United States economy through proven,investments in children. ...
... motivates people to stay active, helps reduce arthritis ... pain ... announced today a,partnership with McNeil Consumer Healthcare, the maker of TYLENOL(R),Arthritis ... and reduce arthritis pain. Through this new collaboration,participating YMCAs will introduce ...
... was issued by The Mesothelioma Applied Research, Foundation ... House, Energy and Commerce Committee on the "Bruce Vento ... Thursday, February 28, 2008. The Meso,Foundation is urging the ... step-up to the plate in allocating research funds for ...
... Commission Director General for Enterprise & Industry Heinz Zourek today ... an EC budget of 624 million to ESA as a ... , This will be provided in two stages: 419 million ... the GSC programme. Segment 2 will be submitted for subscription ...
Other Medicine News:Health News:UB's bioblower closer to protecting soldiers from biological attack 2Health News:UB's bioblower closer to protecting soldiers from biological attack 3Health News:Milestone Scientific Hosts First International Computer-Controlled Local Anesthetic Delivery (CCLAD) Summit 2Health News:Milestone Scientific Hosts First International Computer-Controlled Local Anesthetic Delivery (CCLAD) Summit 3Health News:Milestone Scientific Hosts First International Computer-Controlled Local Anesthetic Delivery (CCLAD) Summit 4Health News:Milestone Scientific Hosts First International Computer-Controlled Local Anesthetic Delivery (CCLAD) Summit 5Health News:Business Leaders, Policy Makers and Advocates Gather to Discuss Strategies for Securing the Nation's Economy by Investing in Early Childhood 2Health News:Business Leaders, Policy Makers and Advocates Gather to Discuss Strategies for Securing the Nation's Economy by Investing in Early Childhood 3Health News:YMCA of the USA and McNeil Consumer Healthcare Partner to Promote Health for Older Adults 2Health News:YMCA of the USA and McNeil Consumer Healthcare Partner to Promote Health for Older Adults 3Health News:Leading Asbestos-Cancer Group Urges Congress to Partner with Them and Support Funding Provisions in Asbestos Ban Legislation 2Health News:Leading Asbestos-Cancer Group Urges Congress to Partner with Them and Support Funding Provisions in Asbestos Ban Legislation 3Health News:Space sentinels: New 'tools' in space to improve European environment and security policies 2Health News:Space sentinels: New 'tools' in space to improve European environment and security policies 3
Hydrodissection / Aspiration Cannula, 25 g. Angled with left hook. 10 mm angled shaft with 2.5 mm left hook tip. Overall length 20 mm. 5/box....
Irrigating Capsulorhexis Cystotome. Formed angled tip, 27 g. Overall length 16 mm. 5/box....
Irrigating Cystotome, formed, 23 g., 12 mm curved tip. Overall length 14 mm. 5/box....
Retrobulbar Needle, 23 g. Atkinson style bevel. Overall length 38 mm. 5/box....
Medicine Products: